The pathophysiology, diagnosis, and treatment of dry eye disease

Elisabeth M Messmer, Elisabeth M Messmer

Abstract

Background: Dry eye disease (DED) is common; its prevalence around the world varies from 5% to 34%. Its putative pathogenetic mechanisms include hyperosmolarity of the tear film and inflammation of the ocular surface and lacrimal gland. Dry eye is clinically subdivided into two subtypes: one with decreased tear secretion (aqueous-deficient DED), and one with increased tear evaporation (hyperevaporative DED).

Methods: This review is based on pertinent publications retrieved by a selective PubMed search and on the authors' own clinical and scientific experience.

Results: The diagnostic evaluation of dry eye disease should include a detailed patient history, thorough split-lamp examination, and additional tests as indicated. Few randomized controlled therapeutic trials for dry eye have been published to date. Artificial tears of various kinds are recommended if the symptoms are mild. Lid hygiene is helpful in the treatment of hyperevaporative dry eye, while collagen or silicon plugs can be used for partial occlusion of the efferent lacrimal ducts to treat severe hyposecretory dry eye. The benefit of long-term topical anti-inflammatory treatment of moderate or severe dry eye disease with corticosteroids or cyclosporine A eye drops has been documented in clinical trials on a high evidence level. Orally administered tetraycycline derivatives and omega-3 or omega-6 fatty acids are also used.

Conclusion: The treatment of dry eye has evolved from tear substitution alone to a rationally based therapeutic algorithm. Current research focuses on pathophysiology, new diagnostic techniques, and novel therapies including secretagogues, topical androgens, and new anti- inflammatory drugs.

Figures

Figure 1
Figure 1
Meibomian gland dysfunction a) Meibomian gland orifices on the eyelid margin blocked by thickened meibomian secretion b) Appearance of healthy meibomian glands on meibography
Figure 2
Figure 2
Lid-parallel conjunctival folds (grade 1 according to Höh et al. [22])
Figure 3
Figure 3
Vital staining of the ocular surface in a patient with dry eye disease a) Fluorescein staining of the cornea b) Lissamine green staining of the conjunctiva
Figure 4
Figure 4
Semiquantitative assessment of surface staining. The van Bijsterveld Index divides the ocular surface into three regions: cornea, nasal conjunctiva, and temporal conjunctiva. Each zone is scored for severity on a scale of 0 to 3. The sum of the three zone scores gives the overall score. Values >3.5 are regarded as pathological (1)
Figure 5
Figure 5
Measuring tear film break-up time to assess tear film stability. a) Invasive method, using fluorescein and the slit lamp with a cobalt blue filter b) Noninvasive method, without fluorescein, using a keratograph. The exact time and area of break-up are determined
Figure 6
Figure 6
Schirmer test to measure tear secretion

References

    1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5:75–92.
    1. Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32:19–41.
    1. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90–100.
    1. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–478.
    1. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003;31:229–232.
    1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–326.
    1. Ruprecht KW, Giere W, Wulle KG. Statistical contribution on symptomatic dry eye. Ophthalmologica. 1977;174:65–74.
    1. Bron AJ, Tomlinson A, Foulks GN, et al. Rethinking dry eEye disease: A perspective on clinical implications. Ocul Surf. 2014;12:1–31.
    1. Ridder WH, Zhang Y, Huang JF. Evaluation of reading speed and contrast sensitivity in dry eye disease. Optom Vis Sci. (3rd) 2013;90:37–44.
    1. Deschamps N, Ricaud X, Rabut G, Labbe A, Baudouin C, Denoyer A. The impact of dry eye disease on visual performance while driving. Am J Ophthalmol. 2013;156:184–189.
    1. Li M, Gong L, Chapin WJ, Zhu M. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012;53:5722–5727.
    1. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412–1419.
    1. Labbe A, Wang YX, Jie Y, Baudouin C, Jonas JB, Xu L. Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study. Br J Ophthalmol. 2013;97:1399–1403.
    1. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30:379–387.
    1. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107–126.
    1. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5:163–178.
    1. Sullivan BD, Crews LA, Messmer EM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014;92:161–166.
    1. Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5:108–152.
    1. Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB. The interblink interval in normal and dry eye subjects. Clin Ophthalmol. 2013;7:253–259.
    1. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008;115:911–915.
    1. Nemeth J, Fodor E, Lang Z, et al. Lid-parallel conjunctival folds (LIPCOF) and dry eye: a multicentre study. Br J Ophthalmol. 2012;96:1380–1385.
    1. Höh H, Schirra F, Kienecker C, Ruprecht KW. Lid-parallel conjunctival folds are a sure diagnostic sign of dry eye. Ophthalmologe. 1995;92:802–808.
    1. Jacobi C, Cursiefen C. Ophthalmological complications in Sjogren’s syndrome. Z Rheumatol. 2010;69:32–40.
    1. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
    1. Liew MS, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren’s syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol. 2012;96:1498–1503.
    1. Messmer EM. Preservatives in ophthalmology. Ophthalmologe. 2012;109:1064–1070.
    1. Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89:1654–1661.
    1. Geerling G, Unterlauft JD, Kasper K, Schrader S, Opitz A, Hartwig D. Autologous serum and alternative blood products for the treatment of ocular surface disorders. Ophthalmologe. 2008;105:623–631.
    1. Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252:619–626.
    1. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811–816.
    1. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 05%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–457.
    1. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–639.
    1. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258–263.
    1. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci. 2011;52:2525–2531.
    1. Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29:781–788.
    1. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22:97–101.
    1. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050–2064.
    1. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR. The clinical efficacy of silicone punctal plug therapy. Cornea. 2002;21:135–139.
    1. Horwath-Winter J, Thaci A, Gruber A, Boldin I. Long-term retention rates and complications of silicone punctal plugs in dry eye. Am J Ophthalmol. 2007;144:441–444.
    1. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2010 CD006775.
    1. Goyal S, Chauhan SK, El Annan J, et al. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? Arch Ophthalmol. 2010;128:819–824.
    1. Heiligenhaus A, Koch JM, Kruse FE, Schwarz C, Waubke TN. Diagnosis and and differentiation of dry eye disorders]. Diagnostik und Differenzierung von Benetzungsstörungen. Der Ophthalmologe. 1995;92:6–11.
    1. Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci. 2010;51:3449–3454.
    1. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096–1101.
    1. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114–1119.
    1. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268.
    1. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Archiv Intern Med. 1999;159:1359–1363.
    1. Kim JH, Kim JH, Nam WH, et al. Oral alcohol administration disturbs tear film and ocular surface. Ophthalmology. 2012;119:965–971.
    1. Thomas J, Jacob GP, Abraham L, Noushad B. The effect of smoking on the ocular surface and the precorneal tear film. Australas Med J. 2012;5:221–226.
    1. Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology. 1999;106:939–943.
    1. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409–415.
    1. Sullivan RM, Cermak JM, Papas AS, Dana MR, Sullivan DA. Economic and quality of life impact of dry eye symptoms in women with Sjogren’s syndrome. Adv Exp Med Biol. 2002;506:1183–1188.
    1. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799–806.
    1. Golubovic S, Parunovic A. Corneal perforation in dry eye patients. Fortschr Ophthalmol. 1987;84:33–37.
    1. Inagaki E, Ogawa Y, Matsumoto Y, et al. Four cases of corneal perforation in patients with chronic graft-versus-host disease. Mol Vis. 2011;17:598–606.
    1. Krachmer JH, Laibson PR. Corneal thinning and perforation in Sjogren’s syndrome. Am J Ophthalmol. 1974;78:917–920.
    1. Messmer EM, Hoops JP, Kampik A. Bilateral recurrent calcareous degeneration of the cornea. Cornea. 2005;24:498–502.
    1. Petroutsos G, Paschides CA, Kitsos G, Drosos AA, Psilas K. Sterile corneal ulcers in dry eye. II. Treatment, complications and course. J Fr Ophtalmol. 1992;15:106–111.
    1. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogren’s syndrome. Archiv Ophthalmol. 1980;98:89–94.
    1. Stevenson W, Shikari H, Saboo US, Amparo F, Dana R. Bilateral corneal ulceration in ocular graft-versus-host disease. Clin Ophthalmol. 2013;7:2153–2158.
    1. Turgut B, Aydemir O, Kaya M, et al. Spontaneous corneal perforation in a patient with lamellar ichthyosis and dry eye. Clin Ophthalmol. 2009;3:611–613.
    1. Henrich CF, Ramulu PY, Akpek EK. Association of dry eye and inflammatory systemic diseases in a tertiary care-based sample. Cornea. 2014;33:819–825.
    1. Abetz L, Rajagopalan K, Mertzanis P, et al. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011;9
    1. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Archiv Ophthalmol. 2000;118:615–621.
    1. Bentivoglio AR, Bressman SB, Cassetta E, et al. Analysis of blink rate patterns in normal subjects. Mov Disord. 1997;12:1028–1034.
    1. Freudenthaler N, Neuf H, Kadner G, Schlote T. Characteristics of spontaneous eyeblink activity during video display terminal use in healthy volunteers. Graefes Arch Clin Exp Ophthalmol. 2003;241:914–920.
    1. Bron AJ, Yokoi N, Gaffney EA, Tiffany JM. A solute gradient in the tear meniscus. I. A hypothesis to explain Marx’s line. Ocul Surf 201. 9:70–91.
    1. Werkmeister RM, Alex A, Kaya S, et al. Measurement of tear film thickness using ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:5578–5583.
    1. Mainstone JC, Bruce AS, Golding TR. Tear meniscus measurement in the diagnosis of dry eye. Curr Eye Res. 1996;15:653–661.
    1. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151:792–798.
    1. Messmer EM, Bulgen M, Kampik A. Hyperosmolarity of the tear film in dry eye syndrome. Dev Ophthalmol. 2010;45:129–138.
    1. Sambursky R, Davitt WF, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol. (3rd) 2013;131:24–28.
    1. Barabino S, Rolando M, Nardi M, et al. The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye. Eur J Ophthalmol. 2014;24:173–178.
    1. Cohen S, Martin A, Sall K. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol. 2014;8:157–164.
    1. Diaz-Valle D, Arriola-Villalobos P, Garcia-Vidal SE, et al. Effect of lubricating eyedrops on ocular light scattering as a measure of vision quality in patients with dry eye. J Cataract Refract Surg. 2012;38:1192–1197.
    1. Doughty MJ. Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a systematic review and meta-analysis. Ocul Surf. 2014;12:100–111.
    1. Lee JH, Ahn HS, Kim EK, Kim TI. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011;30:175–179.
    1. Zhang Y, Potvin R, Gong L. A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjogren’s syndrome. Invest Ophthalmol Vis Sci. 2013;54:7977–7982.
    1. Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye. 2010;33:83–87.
    1. Goto E, Shimazaki J, Monden Y, et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology. 2002;109:2030–2035.
    1. Khanal S, Tomlinson A, Pearce EI, Simmons PA. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. Cornea. 2007;26:175–181.
    1. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119–125.
    1. Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res. 1999;68:541–546.
    1. Baiza-Duran L, Medrano-Palafox J, Hernandez-Quintela E, Lozano-Alcazar J, Alaniz-de la OJ. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94:1312–1315.
    1. Demiryay E, Yaylali V, Cetin EN, Yildirim C. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37:312–315.
    1. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.
    1. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492–496.
    1. Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 003% tacrolimus eye drops. Cornea. 2012;31:945–949.
    1. Sanz-Marco E, Udaondo P, Garcia-Delpech S, Vazquez A, Diaz-Llopis M. Treatment of refractory dry eye associated with graft versus host disease with 003% tacrolimus eyedrops. J Ocul Pharmacol Ther. 2013;29:776–783.
    1. Auw-Hadrich C, Reinhard T. [Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors]. Behandlung der chronischen Blepharokeratokonjunktivitis mit lokalen Kalzineurininhibitoren. Ophthalmologe. 2009;106:635–638.
    1. Kuzin II, Snyder JE, Ugine GD, et al. Tetracyclines inhibit activated B cell function. Int Immunol. 2001;13:921–931.
    1. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41:2544–2557.
    1. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003;76:417–420.
    1. Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871–877.
    1. McCulley JP, Shine WE. Meibomian secretions in chronic blepharitis. Adv Exp Med Biol. 1998;438:319–326.
    1. Guillon M, Maissa C, Wong S. Eyelid margin modification associated with eyelid hygiene in anterior blepharitis and meibomian gland dysfunction. Eye Contact Lens. 2012;38:319–325.
    1. Matsumoto Y, Dogru M, Goto E, et al. Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction. Cornea. 2006;25:644–650.
    1. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.
    1. Purslow C. Evaluation of the ocular tolerance of a novel eyelid-warming device used for meibomian gland dysfunction. Contact Lens Anterior Eye. 2013;36:226–231.
    1. Finis D, Hayajneh J, Konig C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. 2014;12:146–154.
    1. Cohen EJ. Punctal occlusion. Arch Ophthalmol. 1999;117:389–390.
    1. Dursun D, Ertan A, Bilezikci B, Akova YA, Pelit A. Ocular surface changes in keratoconjunctivitis sicca with silicone punctum plug occlusion. Curr Eye Res. 2003;26:263–269.
    1. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26:805–809.
    1. Dimit R, Gire A, Pflugfelder SC, Bergmanson JP. Patient ocular conditions and clinical outcomes using a PROSE scleral device. Cont Lens Anterior Eye. 2013;36:159–163.
    1. Geerling G, Collin JR, Dart JK. Ophthalmic experience with submandibular gland transplantation for severe dry eyes. Laryngoscope. 2009;119:1445–1446.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe